select a format

Single User License
USD 2000 INR 128580
Site License
USD 4000 INR 257160
Corporate User License
USD 6000 INR 385740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Mucopolysaccharidosis II MPS II Hunter Syndrome -Pipeline Review, H1 2016

Mucopolysaccharidosis II MPS II Hunter Syndrome -Pipeline Review, H1 2016


  • Products Id :- GMDHC8198IDB
  • |
  • Pages: 67
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline Review, H1 2016', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

The report reviews pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics and enlists all their major and minor projects

The report assesses Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview 7

Therapeutics Development 8

Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Overview 8

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Therapeutics under Development by Companies 9

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Products under Development by Companies 14

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Companies Involved in Therapeutics Development 15

Alexion Pharmaceuticals, Inc. 15

AngioChem Inc. 16

ArmaGen Inc. 17

Bioasis Technologies Inc. 18

Green Cross Corporation 19

Inventiva 20

JCR Pharmaceuticals Co., Ltd. 21

Laboratorios Del Dr. Esteve S.A. 22

RegenxBio Inc. 23

Sangamo BioSciences, Inc. 24

Shire Plc 25

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

AGT-182-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

EGT-301-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

idursulfase-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

idursulfase beta-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

JR-032-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

JR-141-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

MTf-I2S-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

MTfp-I2S-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

odiparcil-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

pentosan polysulfate sodium-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Recombinant Enzymes for Pompe, Fabry and Hunter Diseases-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

RGX-121-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SB-913-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Dormant Projects 54

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Discontinued Products 55

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Product Development Milestones 56

Featured News & Press Releases 56

Apr 19, 2016: Preclinical Data from REGENXBIO's RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting 56

Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome 57

Jul 31, 2015: Bioasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome 57

Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital 58

Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire 59

Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial 59

Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome 60

Sep 18, 2014: Bioasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation 61

Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome 62

Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria 62

Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 63

Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press 63

Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome 64

Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase 65

Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Figures

Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 12

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Targets, H1 2016 27

Number of Products by Stage and Targets, H1 2016 27

Number of Products by Mechanism of Actions, H1 2016 29

Number of Products by Stage and Mechanism of Actions, H1 2016 29

Number of Products by Routes of Administration, H1 2016 31

Number of Products by Stage and Routes of Administration, H1 2016 31

Number of Products by Molecule Types, H1 2016 33

Number of Products by Stage and Molecule Types, H1 2016 33

List of Tables

Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2016 8

Number of Products under Development by Companies, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 11

Comparative Analysis by Early Stage Development, H1 2016 12

Comparative Analysis by Unknown Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 15

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by AngioChem Inc., H1 2016 16

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by ArmaGen Inc., H1 2016 17

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Bioasis Technologies Inc., H1 2016 18

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Green Cross Corporation, H1 2016 19

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Inventiva, H1 2016 20

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2016 21

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 22

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by RegenxBio Inc., H1 2016 23

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Sangamo BioSciences, Inc., H1 2016 24

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Pipeline by Shire Plc, H1 2016 25

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Stage and Target, H1 2016 28

Number of Products by Stage and Mechanism of Action, H1 2016 30

Number of Products by Stage and Route of Administration, H1 2016 32

Number of Products by Stage and Molecule Type, H1 2016 34

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Dormant Projects, H1 2016 54

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )-Discontinued Products, H1 2016 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alexion Pharmaceuticals, Inc.

AngioChem Inc.

ArmaGen Inc.

Bioasis Technologies Inc.

Green Cross Corporation

Inventiva

JCR Pharmaceuticals Co., Ltd.

Laboratorios Del Dr. Esteve S.A.

RegenxBio Inc.

Sangamo BioSciences, Inc.

Shire Plc

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutic Products under Development, Key Players in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics, Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Pipeline Overview, Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Pipeline, Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com